The objective of this study was to determine the clinical features of 44 patients with anticentromere antibody (ACA) positivity. We undertook a retrospective review of 44 ACA-positive patients (1 male and 43 females with a mean±SD age of 53.6±12.2 years). There were 25 patients with limited systemic sclerosis, 12 with Raynaud's disease, 2 with Sjögren's syndrome, 2 with systemic lupus erythematosus and 3 with polyarthritis. ACA was more frequently found in patients affected by limited systemic sclerosis with mild visceral involvement and in patients with Raynaud's disease. Moreover, ACA was detected in other connective tissue diseases that were characterized by an atypical autoantibody profile.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Weiner ES, Earnshaw WC, Senécal JL, Bordwell B, Johnson P, Rothfield NF (1988) Clinical associations of anticentromere antibodies and antibodies to topoisomerase. I. A study of 355 patients. Arthritis Rheum 31:378–385
Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526
Catoggio LJ, Skinner RP, Maddison PJ (1983) Frequency and clinical significance of anticentromere and anti-Scl-70 antibodies in an English connective tissue disease population. Rheumatol Int 3:19–21
LeRoy EC, Krieg T, Black C, Medsger TA Jr, Fleischmajer R, Rowell N, Jablonska S, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–204
Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnosis and evolution. Br J Rheumatol 32:297–301
Bernstein RM, Callender ME, Neuberger JM (1982) Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41:612–614
Wade JP, Sack B, Schur PH (1988) Anticentromere antibodies—clinical correlates. J Rheumatol 15:1759–1763
Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G, Neri R, Bombardieri S (1991) Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 18:1826–1832
Haberhauer G (1989) D-penicillamine (DPA)-induced anticentromere antibody (ACA). Clin Exp Rheumatol 7:332–334
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Kraaijenhagen HA (1975) Technique for parotid biopsy. J Oral Surg 33:328
Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M (1986) Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13:911–916
Maricq HR, Weinberger AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy. J Rheumatol 9:289–291
Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–692
About this article
Cite this article
Caramaschi, P., Manzo, T., Biasi, D. et al. Anticentromere antibody — clinical associations. Rheumatol Int 14, 253–255 (1995). https://doi.org/10.1007/BF00262092
- Anticentromere antibody
- Limited systemic sclerosis
- CREST syndrome
- Raynaud's phenomenon